Cellistic

Executive Summary

Cellistic is a Belgian Contract Development and Manufacturing Organization (CDMO) founded in 2022, specializing in induced pluripotent stem cell (iPSC)-based cell therapies. The company offers end-to-end services from cell line development to GMP manufacturing, with a focus on enabling scalable allogeneic therapies for immune-oncology and regenerative medicine. By leveraging proprietary iPSC technology, Cellistic aims to reduce the scientific and economic barriers that currently limit the widespread adoption of cell therapies. As a private company headquartered in Ghent, Belgium, it operates in a rapidly growing niche, serving a pipeline of biotech and pharmaceutical clients developing off-the-shelf cell therapies. Although early-stage and without publicly disclosed funding or revenue, Cellistic is positioned to capture value from the increasing demand for specialized CDMO capacity in the allogeneic cell therapy space. Given its recent founding and lack of disclosed financials, Cellistic's current impact is uncertain. However, the broader market tailwinds for iPSC-derived therapies and CDMO outsourcing are strong. The company's success hinges on securing contracts with leading cell therapy developers and expanding its manufacturing capabilities. Near-term catalysts could include announcements of strategic partnerships or capacity expansions. The conviction score is moderate, reflecting both the promising market opportunity and the early-stage risks associated with a young, unproven CDMO.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a major partnership with a cell therapy developer40% success
• Q2 2027Completion of GMP facility expansion or new cleanroom capacity60% success
• Q1 2027First contract manufacturing revenue or public funding round50% success